BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9768522)

  • 1. Designer estrogens.
    Jordan VC
    Sci Am; 1998 Oct; 279(4):60-7. PubMed ID: 9768522
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-estrogens come of age: a pioneer looks back.
    Nelson NJ
    J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
    Jordan VC
    J Natl Cancer Inst; 1998 Jul; 90(13):967-71. PubMed ID: 9665143
    [No Abstract]   [Full Text] [Related]  

  • 4. Designer estrogens: breast cancer benefit, remaining questions.
    Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
    [No Abstract]   [Full Text] [Related]  

  • 5. Tamoxifen for prevention of breast cancer.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective estrogen receptor modulators: Women's panacea for the next millennium?
    Spencer CP; Morris EP; Rymer JM
    Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):763-70. PubMed ID: 10076160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women.
    Fitzpatrick LA
    Mayo Clin Proc; 1999 Jun; 74(6):601-7. PubMed ID: 10377937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a new prevention maintenance therapy for postmenopausal women.
    Jordan VC
    Recent Results Cancer Res; 1999; 151():96-109. PubMed ID: 10337721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy.
    Jordan VC; MacGregor JI; Tonetti DA
    Osteoporos Int; 1997; 7 Suppl 1():S52-7. PubMed ID: 9205647
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical effects of raloxifene hydrochloride in women.
    Khovidhunkit W; Shoback DM
    Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
    Bryant HU; Dere WH
    Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogens: clinical applications of pharmacology.
    Jordan VC
    J Soc Gynecol Investig; 2000; 7(1 Suppl):S47-8. PubMed ID: 10732329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
    Cummings SR; Eckert S; Krueger KA; Grady D; Powles TJ; Cauley JA; Norton L; Nickelsen T; Bjarnason NH; Morrow M; Lippman ME; Black D; Glusman JE; Costa A; Jordan VC
    JAMA; 1999 Jun; 281(23):2189-97. PubMed ID: 10376571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor as a target for the prevention of breast cancer.
    Jordan VC
    J Lab Clin Med; 1999 May; 133(5):408-14. PubMed ID: 10235123
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted anti-estrogens to treat and prevent diseases in women.
    Tonetti DA; Jordan VC
    Mol Med Today; 1996 May; 2(5):218-23. PubMed ID: 8796891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene: a selective estrogen receptor modulator.
    Scott JA; Da Camara CC; Early JE
    Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encouraging news from the SERM frontier. Selective estrogen receptor modulator.
    Franks AL; Steinberg KK
    JAMA; 1999 Jun; 281(23):2243-4. PubMed ID: 10376579
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective estrogen receptor modulators and postmenopausal women's health.
    Hol T; Cox MB; Bryant HU; Draper MW
    J Womens Health; 1997 Oct; 6(5):523-31. PubMed ID: 9356975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer.
    Dove A
    Nat Med; 1998 Jun; 4(6):647. PubMed ID: 9623955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.